Diabetes Clinical Trial Pipeline Experiences Rapid Expansion as Over 200+ Leading Companies Advance Novel Therapies
Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight's comprehensive report today! @ Diabetes Pipeline Outlook
Key Takeaways from the Diabetes Pipeline Report
In June 2025, Eli Lilly and Company announced a study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
The leading Diabetes Companies such as vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others.
Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others.
Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs
Diabetes Emerging Drugs Profile
Cadisegliatin: vTv Therapeutics
Cadisegliatin, also known as TTP399, is an innovative oral medication developed by vTv Therapeutics, designed as a liver-selective glucokinase activator. It aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). This drug has been recognized for its potential to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage independently of insulin, addressing a critical need in diabetes management. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diabetes.
LY-3209590: Eli Lilly and Company
Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes.
CT-388: Roche
CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). CT-388 was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no ß-arrestin recruitment on either receptor. This biased signaling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Type 2 Diabetes Mellitus.
HU6: Rivus Pharmaceuticals
HU6 is an investigational, first-in-class oral therapy developed by Rivus Pharmaceuticals. It belongs to a new drug class called Controlled Metabolic Accelerators (CMAs), which are designed to selectively increase fat metabolism, leading to fat loss while preserving muscle mass. HU6 works by subtly increasing resting metabolism, specifically by activating a process called mitochondrial uncoupling. This process increases the oxidation of sugars and fats without reducing ATP (energy) production, resulting in the selective reduction of accumulated fat throughout the body. Currently, the drug is in the Phase II stage of development to treat Diabetes.
XW014: Sciwind Biosciences
XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes.
K-833: Kallyope Inc.
K-833 is an investigational oral small-molecule developed by Kallyope Inc., designed as a nutrient receptor agonist for the treatment of obesity and type 2 diabetes. K-833, often studied in combination with Kallyope's other candidate K-757, targets G-protein coupled receptors (specifically GPR119), which are involved in the release of hormones that suppress appetite and regulate glucose. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes.
The Diabetes Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment.
Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market
Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight's detailed report now! @ New Diabetes Drugs
Diabetes Companies
vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others.
The Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diabetes Products have been categorized under various Molecule types such as,
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers
Scope of the Diabetes Pipeline Report
Coverage- Global
Diabetes Companies- vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others.
Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others.
Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Diabetes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diabetes– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Cadisegliatin: vTv Therapeutics
Drug profiles in the detailed report…..
Mid-Stage Products (Phase II)
CPL207280: Celon Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
KN056: Suzhou Alphamab Co., Ltd.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diabetes Key Companies
Diabetes Key Products
Diabetes- Unmet Needs
Diabetes- Market Drivers and Barriers
Diabetes- Future Perspectives and Conclusion
Diabetes Analyst Views
Diabetes Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical trial titled A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. The study aims to assess the safety and tolerability of the drugs AZD2284, AZD2287, and AZD2275 in treating this aggressive form of prostate cancer. The trial is testing three drugs: AZD2284, AZD2287, and AZD2275, all administered via intravenous methods. AZD2284 is the primary focus, with the goal of determining its optimal dosing and efficacy in conjunction with the other two drugs. This non-randomized, open-label study follows a sequential intervention model. It is primarily focused on treatment, with no masking involved, allowing for direct observation of the drug effects. The study began on March 10, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they indicate the study's progress and the timeline for potential results. This study's update could influence AstraZeneca's stock performance positively, as successful results may enhance investor confidence and market position in the oncology sector. Competitors in the prostate cancer treatment market will be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.
Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma. The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule. This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study. The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates to stakeholders. The ongoing study may influence AstraZeneca's stock performance and investor sentiment, as successful outcomes could enhance the company's oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's Osimertinib Study: A Potential Game-Changer for NSCLC Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a study titled 'Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France' to evaluate the effectiveness of osimertinib in treating locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating EGFR mutations. The study aims to assess the 36-month overall survival rate, patient characteristics, disease progression, treatment patterns, and quality of life. The intervention being tested is osimertinib, a drug used as a first-line treatment for NSCLC patients with specific genetic mutations. It is designed to target and inhibit the growth of cancer cells. This observational study employs a multicenter design, combining a cross-sectional survey and a prospective cohort model. It focuses on real-life treatment scenarios to gather comprehensive data on patient outcomes and treatment efficacy. The study began on May 12, 2021, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and ensuring timely analysis of the data collected. The study's findings could significantly impact AstraZeneca's stock performance by demonstrating the effectiveness of osimertinib, potentially boosting investor confidence. It also positions AstraZeneca competitively within the oncology market, particularly against other companies developing treatments for NSCLC. The study is ongoing, with further details available on the ClinicalTrials portal.
